Thermo Fisher Scientific Inc (TMO) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $469.63, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.
Thermo Fisher Scientific serves pharmaceutical, biotech, academic, government, and clinical customers globally across Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services segments. With ~125,000 employees across 60+... Read more
Hold if already holding. Not a fresh buy at $469.63, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Death cross but MACD improving, RSI 64. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Thermo Fisher Scientific Inc
Latest news
- NEWS Thermo Fisher shareholders reject say-on-pay at annual meeting - The Globe and Mail — The Globe and Mail negative
- NEWS Annex Advisory Services LLC Acquires 3,469 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat — MarketBeat neutral
- NEWS TMO Maintains Overweight Rating by Barclays -- Price Target Lowe - GuruFocus — GuruFocus positive
- NEWS Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day - Slideshow (NYSE:TMO) 2026-05-26 - Seeking Alpha — Seeking Alpha positive
- NEWS TD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Insider Monkey — Insider Monkey neutral
Generated 2026-06-09T22:26:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $469.63, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Death cross but MACD improving, RSI 64. Maintain position. Not compelling to add more. Target $542.48 (+15.5%), stop $440.87 (−6.5%), A.R:R 2.1:1. Score 5.2/10, moderate confidence.
Take-profit target: $542.48 (+15.5% upside). Target $542.48 (+15.5%), stop $440.87 (−6.5%), A.R:R 2.1:1. Stop-loss: $440.87.
Thermo Fisher Scientific Inc trades at a P/E of 26.0 (forward 17.3). TrendMatrix value score: 5.7/10. Verdict: Hold.
34 analysts cover TMO with a consensus score of 4.2/5. Average price target: $603.
What does Thermo Fisher Scientific Inc do?Thermo Fisher Scientific serves pharmaceutical, biotech, academic, government, and clinical customers globally across...
Thermo Fisher Scientific serves pharmaceutical, biotech, academic, government, and clinical customers globally across Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services segments. With ~125,000 employees across 60+ countries, it provides instruments, reagents, consumables, and outsourced biopharma development and manufacturing services.